References
- Gilpin B J, Loechel F, Mattei M G, Engvall E, Albrechtsen R, Wewer U M. A novel, secreted form of human ADAM12 (meltrin α) provokes myogenesis in vivo. J Biol Chem 1998; 273: 157–166
- Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98: 621–628
- Thodeti C K, Frohlich C, Nielsen C K, Takada Y, Fassler R, Albrechtsen R, Wewer U M. ADAM12-mediated focal adhesion formation is differently regulated by β1 and β3 integrins. FEBS Lett 2005; 579: 5589–5595
- Loechel F, Gilpin B J, Engvall E, Albrechtsen R, Wewer U M. Human ADAM12 (meltrin α) is an active metalloprotease. J Biol Chem 1998; 273: 16993–16997
- Shi Z, Xu W, Loechel F, Wewer U M, Murphy L J. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275: 18574–18580
- Laigaard J, Sorensen T, Frohlich C, Pedersen B N, Christiansen M, Schiott K, Uldbjerg N, Albrechtsen R, Clausen H V, Ottesen B, et al. ADAM12: a novel first-trimester maternal serum marker for down syndrome. Prenat Diagn 2003; 23: 1086–1091
- Laigaard J, Christiansen M, Frohlich C, Pedersen B N, Ottesen B, Wewer U M. The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18. Prenat Diagn 2005; 25: 45–46
- Laigaard J, Cuckle H, Wewer U M, Christiansen M. Maternal serum ADAM12 levels in Down and Edwards' syndrome pregnancies at 9–12 weeks' gestation. Prenat Diagn 2006; 26: 689–691
- Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann K R, Sundberg K, Shalmi A C, Tabor A, Norgaard-Pedersen B, et al. Reduction of the disintegrin and metalloprotease ADAM12 in pre-eclampsia. Obstet Gynecol 2005; 106: 144–149
- Cowans N J, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007; 27: 264–271
- Poon L CY, Chelemen T, Minekawa R, Frisova V, Nicolaides K H. Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11–13 weeks. Am J Obstet Gyn 2009; 200: 508e1–508e6
- Laigaard J, Spencer K, Christiansen M, Cowans N J, Larsen S O, Pedersen B N, Wewer U M. ADAM12 as a first-trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 2006; 26: 973–979
- Nicolaides K H, Chervenak F A, McCullough L B, Avgidou K, Papageorghiou A. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21. Am J Obstet Gynecol 2005; 193: 322–326